Enliven Therapeutics Inc Quick Ratio (ELVN) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Enliven Therapeutics Inc   (NASDAQ: ELVN)

Enliven Therapeutics Inc 's Quick Ratio

ELVN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 116.86 above Enliven Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Quick Ratio than Enliven Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 25, from total ranking in the first quarter 2026 at 40.

Explain Quick Ratio?
How much Cash & cash equivalents ELVN´s has?
What are ELVN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ELVN Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 502.34 % 4.99 % 60.88 % 40.24 % -89.36 %
Y / Y Cash & cash equivalent Change 237.38 % 56.24 % 47.59 % 63.64 % 57.02 %
Quick Ratio MRQ 116.86 275.85 214.28 334.2 208.64
ELVN's Total Ranking # 25 # 40 # 35 # 40 # 48
Seq. Current Liabilities Change 763.48 % -24.04 % 51.08 % -39.22 % 50.51 %
Seq. Cash & cash equivalent Change 265.79 % -2.21 % -3.13 % -2.64 % 69.4 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 3
Healthcare Sector # 4
Overall Market # 42


Quick Ratio Statistics
High Average Low
334.2 78.64 0
(Sep 30 2025)   (Sep 30 2012)




Financial Statements
Enliven Therapeutics Inc 's Current Liabilities $ 14 Millions Visit ELVN's Balance sheet
Enliven Therapeutics Inc 's Cash & cash equivalent $ 1,655 Millions Visit ELVN's Balance sheet
Source of ELVN's Sales Visit ELVN's Sales by Geography


Cumulative Enliven Therapeutics Inc 's Quick Ratio

ELVN's Quick Ratio for the trailling 12 Months

ELVN Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 209.04 % -70.88 % -84.85 % -90.97 % -91.58 %
Y / Y Cash & cash equivalent TTM Growth 119.98 % 55.99 % 38.93 % 33.38 % 20.51 %
Quick Ratio TTM 157.17 248.46 229.34 235.05 220.81
Total Ranking TTM # 178 # 233 # 131 # 138 # 174
Seq. Current Liabilities TTM Growth 155.83 % 1.04 % 12.22 % 6.53 % -75.9 %
Seq. Cash & cash equivalent TTM Growth 61.83 % 9.47 % 9.5 % 13.41 % 14.75 %

Quick ratio ranking by company, industry and sector >> Back to ELVN Financial Strength Comparisons >> Go to Compare ELVN Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q2 2026 to $14.16 millions, cumulative Quick Ratio decreased to 157.17 above the ELVN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 398 other companies have achieved higher Quick Ratio than Enliven Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 1999.

Explain Quick Ratio?
How much Cash & cash equivalents ELVN´s has?
What are ELVN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 399
Healthcare Sector # 782
Within the Market # 25


trailing twelve months Quick Ratio Statistics
High Average Low
21.59 10.52 0.01
(Jun 30 2026)   (Sep 30 2012)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Mira Pharmaceuticals Inc   198.75 $ 8.113  Millions$ 0.041  Millions
Veradermics Inc  139.85 $ 1,635.362  Millions$ 11.694  Millions
Enliven Therapeutics Inc   116.86 $ 1,654.850  Millions$ 14.161  Millions
Acrivon Therapeutics Inc   104.48 $ 89.959  Millions$ 0.861  Millions
Arca Biopharma Inc  87.05 $ 2,225.581  Millions$ 25.566  Millions
Tango Therapeutics Inc   82.19 $ 1,668.432  Millions$ 20.299  Millions
Contineum Therapeutics Inc   70.25 $ 458.440  Millions$ 6.526  Millions
Sagimet Biosciences inc   61.23 $ 331.832  Millions$ 5.419  Millions
Avalyn Pharma Inc   49.93 $ 539.733  Millions$ 10.809  Millions
Pasithea Therapeutics Corp   49.76 $ 91.464  Millions$ 1.838  Millions
Disc Medicine Inc   44.03 $ 1,336.770  Millions$ 30.360  Millions
Trevi Therapeutics Inc   36.50 $ 318.870  Millions$ 8.736  Millions
Design Therapeutics Inc   35.76 $ 401.889  Millions$ 11.240  Millions
Mineralys Therapeutics Inc   34.87 $ 673.704  Millions$ 19.319  Millions
Praxis Precision Medicines Inc   34.32 $ 1,683.790  Millions$ 49.058  Millions
Agios Pharmaceuticals Inc   33.94 $ 2,383.112  Millions$ 70.217  Millions
Mbx Biosciences Inc   33.10 $ 783.099  Millions$ 23.660  Millions
Xbiotech Inc   32.67 $ 109.528  Millions$ 3.353  Millions
Avalo Therapeutics Inc   31.89 $ 787.143  Millions$ 24.682  Millions
Fulcrum Therapeutics Inc   30.96 $ 318.840  Millions$ 10.298  Millions
Climb Bio Inc   30.86 $ 183.123  Millions$ 5.934  Millions
Indaptus Therapeutics Inc   29.61 $ 15.554  Millions$ 0.525  Millions
Crinetics Pharmaceuticals Inc   29.41 $ 2,350.275  Millions$ 79.915  Millions
Spyre Therapeutics Inc   28.48 $ 1,100.000  Millions$ 38.620  Millions
Curanex Pharmaceuticals Inc  28.17 $ 2.938  Millions$ 0.104  Millions
Onkure Therapeutics Inc   28.04 $ 186.284  Millions$ 6.643  Millions
Ligand Pharmaceuticals Incorporated  27.33 $ 1,277.438  Millions$ 46.736  Millions
Shattuck Labs Inc   26.94 $ 208.300  Millions$ 7.731  Millions
Cryoport inc   26.87 $ 785.860  Millions$ 29.244  Millions
Roivant Sciences Ltd   26.82 $ 7,607.076  Millions$ 283.603  Millions

Date modified: 2026-09-10T13:15:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.